Sales Results

Discussion in 'Collegium Pharmaceutical' started by anonymous, Nov 18, 2016 at 9:51 AM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    Net product revenues for Xtampza ER were $408,000 for the 2016 Quarter compared to none for the 2015 Quarter.
     

  2. anonymous

    anonymous Guest

    Nice Job!

    The Purdue Boys
     
  3. anonymous

    anonymous Guest

    Sales leadership is horrible! All idiots!
     
  4. anonymous

    anonymous Guest

    Marketing leadership isn't the brightest bulb in the box either
     
  5. anonymous

    anonymous Guest

    Say what you want about this company, they have done a good job entering this market as a start-up and have been able to accomplish a lot of things that nobody would have expected from a small startup company. They are competing with companies that have a ton of market experience and they are doing well in this challenging space. Managed care wins are indicative of a product, technology and a company that many are rallying behind and it is gaining traction. Call them all idiots if you want but these idiots seem
    To know what they are doing moreso than the clowns at my last company that is a pillar in the industry.
     
  6. anonymous

    anonymous Guest

    You are right you have done a great job!
    You are 99% below forecast!

    Major changes underway rookie!
     
  7. anonymous

    anonymous Guest

    Who is having success with this product? I really want to know!
     
  8. anonymous

    anonymous Guest

    This company is a joke, a complete embarrassment!
     
  9. anonymous

    anonymous Guest

    A few quick questions as a prospective teammate - what was your goal and how close are these numbers? what has turnover been like at the field sales, sales leadership, and home office levels? how robust does your pipeline look and what's the timing for approvals? how's the culture? Many thanks in advance!
     
  10. anonymous

    anonymous Guest

    word to the wise--don't do it unless you are desperate!
     
  11. anonymous

    anonymous Guest

    we have made inroads into the pain market...grant it...less than .03% inroads...but inroads nonetheless.
     
  12. anonymous

    anonymous Guest

    Dear collegium,

    we are really scared now!

    Sincerely,

    Purdue
     
  13. anonymous

    anonymous Guest

    Dear Purdue:
    You should be scared.
    Your sales are dwindling,
    Your patent is toast
    You have an inferior product and everyone is realizing that
    Collegium is respected in the managed care arena
    Collegium sales are starting to really take off!
    You have no future
    Morale at your company could not be worse
    Everyone hates your company and doesn't want to do business with your company especially when there's another choice
    Everyone is fleeing from Purdue
    You are now considered a pariah in the industry
    Purdue keeps their employees in the dark and will
    Soon lay off more to help the bottom line
    Managed care is blocking your products because they can't stand your behavior over the years
    Nobody respects you anymore
    Nobody will partner with your company
    The talent that existed is gone
    Butrans is going generic
    Hysingla is not going to support a sales force of 500+
    OxyContin is declining dramatically
    Management couldn't figure out how to diversify
    The fat lady is starting to sing! It's over Purdue!
     
  14. anonymous

    anonymous Guest

    And thats why we have a .3% share and are not worried about our jobs!
     
  15. anonymous

    anonymous Guest

    Collegium knuckle heads (sales and marketing leadership) to the Purdue Boys: "We're not scared Purdue, you're scared!! You're scared!! You're the scardy cat!! You are!! You!! You!! Why should collegium be scared when we have a whopping 0.03% share of the pain market? You better watch out because this time next year we will own the market with a market share of 0.05%!!! Gotta go now, there's work to be done trying to MCGA (make collegium great again)!"